| dc.contributor.author | Jazaeri, Amir A | |
| dc.contributor.author | Grisham, Rachel | |
| dc.contributor.author | Knisely, Anne | |
| dc.contributor.author | Spranger, Stefani | |
| dc.contributor.author | Zamarin, Dmitriy | |
| dc.contributor.author | Hillman, R Tyler | |
| dc.contributor.author | Lawson, Barrett C | |
| dc.contributor.author | Burns, Kathleen H | |
| dc.contributor.author | Lee, Sanghoon | |
| dc.contributor.author | Westin, Shannon N | |
| dc.contributor.author | Moiso, Enrico | |
| dc.contributor.author | Williams, Marc J | |
| dc.contributor.author | Bardhan, Neelkanth M | |
| dc.contributor.author | Pisanic, Thomas | |
| dc.contributor.author | Matulonis, Ursula | |
| dc.contributor.author | Weigelt, Britta | |
| dc.contributor.author | Shih, IeMing | |
| dc.contributor.author | Konstantinopoulos, Panagiotis A | |
| dc.contributor.author | Gaillard, Stephanie | |
| dc.contributor.author | Wang, Linghua | |
| dc.contributor.author | Aghajanian, Carol | |
| dc.contributor.author | D’Andrea, Alan D | |
| dc.contributor.author | Hammond, Paula | |
| dc.contributor.author | Shah, Sohrab | |
| dc.contributor.author | Wucherpfennig, Kai W | |
| dc.contributor.author | Lu, Karen H | |
| dc.date.accessioned | 2025-07-16T19:15:14Z | |
| dc.date.available | 2025-07-16T19:15:14Z | |
| dc.date.issued | 2023-11-10 | |
| dc.identifier.uri | https://hdl.handle.net/1721.1/160689 | |
| dc.description.abstract | Frontline treatment and resultant cure rates in patients with advanced ovarian cancer have changed little over the past several decades. Here, we outline a multidisciplinary approach aimed at gaining novel therapeutic insights by focusing on the poorly understood minimal residual disease phase of ovarian cancer that leads to eventual incurable recurrences. | en_US |
| dc.language.iso | en | |
| dc.publisher | Elsevier BV | en_US |
| dc.relation.isversionof | 10.1016/j.medj.2023.08.004 | en_US |
| dc.rights | Creative Commons Attribution-Noncommercial-ShareAlike | en_US |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | en_US |
| dc.source | PubMed Central | en_US |
| dc.title | Transforming ovarian cancer care by targeting minimal residual disease | en_US |
| dc.type | Article | en_US |
| dc.identifier.citation | Jazaeri, Amir A, Grisham, Rachel, Knisely, Anne, Spranger, Stefani, Zamarin, Dmitriy et al. 2023. "Transforming ovarian cancer care by targeting minimal residual disease." Med, 4 (11). | |
| dc.contributor.department | Koch Institute for Integrative Cancer Research at MIT | en_US |
| dc.relation.journal | Med | en_US |
| dc.eprint.version | Author's final manuscript | en_US |
| dc.type.uri | http://purl.org/eprint/type/JournalArticle | en_US |
| eprint.status | http://purl.org/eprint/status/PeerReviewed | en_US |
| dc.date.updated | 2025-07-16T19:03:13Z | |
| dspace.orderedauthors | Jazaeri, AA; Grisham, R; Knisely, A; Spranger, S; Zamarin, D; Hillman, RT; Lawson, BC; Burns, KH; Lee, S; Westin, SN; Moiso, E; Williams, MJ; Bardhan, NM; Pisanic, T; Matulonis, U; Weigelt, B; Shih, I; Konstantinopoulos, PA; Gaillard, S; Wang, L; Aghajanian, C; D’Andrea, AD; Hammond, P; Shah, S; Wucherpfennig, KW; Lu, KH | en_US |
| dspace.date.submission | 2025-07-16T19:03:15Z | |
| mit.journal.volume | 4 | en_US |
| mit.journal.issue | 11 | en_US |
| mit.license | OPEN_ACCESS_POLICY | |
| mit.metadata.status | Authority Work and Publication Information Needed | en_US |
